Enliven Therapeutics Highlights Business Achievements and Reports First Quarter 2023 Financial Results
11 mai 2023 16h05 HE
|
Enliven Therapeutics, Inc.
Successfully completed merger with Imara Inc., trading under the new ticker symbol on Nasdaq, “ELVN” Dosed first patient in Phase 1 study of ELVN-002 in patients with HER2-altered non-small cell...
Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million
23 févr. 2023 17h20 HE
|
Enliven Therapeutics, Inc.
Combined company will be focused on advancing Enliven’s clinical-stage pipeline of precision oncology programs Shares to trade on Nasdaq under the new ticker symbol “ELVN” on February 24, 2023 ...